University of North Carolina School of Medicine; the American Diabetes AssociationDisclosures
Dr. Buse says, "My employer, the University of North Carolina, has contracted with a variety of companies since
2005 for my services as an investigator, consultant and/or speaker. These are managed by the
Divisional Administrator who makes all decisions about what work I do for what companies and
controls accounts into which receipts are deposited. These funds do benefit the Division. They
do not provide direct benefit to me, but certainly do so indirectly. These companies include
Amylin, Bayhill Therapeutics, BD Research Laboratories, Bristol-Myers Squibb, Dexcom, Eli
Lilly, GlaxoSmithKline, Hoffman-La Roche, Intekrin, Intuity Medical, Johnson & Johnson,
MannKind, Medtronic, Merck, MicroIslet, Novartis, Novo Nordisk, Osiris, Pfizer, sanofi-aventis,
Transition Therapeutics, and Wyeth."
|Program Name||Last Air Date||Hosts/Guests|
|New Treatment Algorithm for Type 2 Diabetes||12/31/2010|
|Do Incretins Play An Important Role In the Cardiovascular System?||09/11/2009|
|Special Report: What Went Wrong With ACCORD?||07/27/2008|
|Diabetes in Children: Refocusing our Practices||11/14/2008|
|Diabetes: Refocusing our Practices||06/15/2008|
You need to be logged in to save this episode to a playlist.
You must be logged in to display playlists.